Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pamapimod (R1503) 是一种新型的选择性 p38 丝裂原活化蛋白激酶抑制剂,对于p38α和p38β的IC50分别为 14 nM 和 480 nM,Ki 分别为 1.3 nM 和 120 nM,对 p38δ 或 p38γ 亚型没有活性,可研究类风湿关节炎和其他自身免疫性疾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 497 | 现货 | ||
5 mg | ¥ 1,230 | 现货 | ||
10 mg | ¥ 1,990 | 现货 | ||
25 mg | ¥ 3,990 | 现货 | ||
50 mg | ¥ 6,390 | 现货 | ||
100 mg | ¥ 8,590 | 现货 | ||
500 mg | ¥ 17,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,370 | 现货 |
产品描述 | Pamapimod (R1503) (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activated protein kinase. It inhibits p38α and p38β enzymatic activity with IC50 values of 0.014±0.002 and 0.48± 0.04 microM, respectively with no activity against p38delta or p38 gamma isoforms. |
靶点活性 | p38β:0.48±0.04 μM, p38α:0.014 ±0.002μM |
体外活性 | Pamapimod inhibited p38, but inhibition of JNK was not detected. Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) α production by monocytes, interleukin (IL)-1β production in human whole blood, and spontaneous TNFα production by synovial explants from RA patients[1]. |
体内活性 | In murine collagen-induced arthritis, pamapimod reduced Clinicalal signs of inflammation and bone loss at 50 mg/kg or greater. In a rat model of hyperalgesia, pamapimod increased tolerance to pressure in a dose-dependent manner, suggesting an important role of p38 in pain associated with inflammation. Pamapimod suppresses spontaneous production of TNFα by synovial explants from RA patients. LPS- and TNFα-stimulated production of TNFα and IL-6 in rodents also was inhibited by pamapimod[1]. |
别名 | R1503, 帕吡莫德, Ro4402257 |
分子量 | 406.38 |
分子式 | C19H20F2N4O4 |
CAS No. | 449811-01-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 27 mg/mL (66.4 mM)
DMSO: 75 mg/mL (184.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.4608 mL | 12.3038 mL | 24.6075 mL | 61.5188 mL |
5 mM | 0.4922 mL | 2.4608 mL | 4.9215 mL | 12.3038 mL | |
10 mM | 0.2461 mL | 1.2304 mL | 2.4608 mL | 6.1519 mL | |
20 mM | 0.123 mL | 0.6152 mL | 1.2304 mL | 3.0759 mL | |
50 mM | 0.0492 mL | 0.2461 mL | 0.4922 mL | 1.2304 mL | |
DMSO | 100 mM | 0.0246 mL | 0.123 mL | 0.2461 mL | 0.6152 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pamapimod 449811-01-2 Autophagy MAPK p38 MAPK Ro-4402257 Inhibitor R1503 IL-6 TNF-α inhibit IL-1β JNK 帕吡莫德 R-1503 p38β Ro 4402257 Ro4402257 p38α anti-inflammation LPS R 1503 inhibitor